BRCA1 16 years later: Risk-associated BRCA1 mutations and their functional implications

FEBS Journal

Volumn 277, Issue 15, 2010, Pages 3086-3096

  Linger, Rebecca J ^a   Kruk, Patricia A ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

BRCA1; breast cancer; mutation; ovarian cancer; risk

Indexed keywords

BRCA1 PROTEIN;

APOPTOSIS; BREAST CANCER; CELL PROLIFERATION; CHEMOSENSITIVITY; DNA DAMAGE; GENE MUTATION; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RISK FACTOR; SHORT SURVEY; SIGNAL TRANSDUCTION;

BRCA1 PROTEIN; FEMALE; HUMANS; MUTATION; RISK FACTORS;

EID: 77954712322     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2010.07735.x     Document Type: Short Survey

References (68)

1. Lux M, Fasching P Beckmann M (2006) Hereditary breast and ovarian cancer: review and future perspectives. J Mol Med 84, 16 28.
2. Ford D, Easton DF, Bishop DT, Narod SA Goldgar DE (1994) Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 343, 692 695.
3. Thompson M (2010) BRCA1 16 years later: nuclear import and export processes. FEBS J 277, 3072 3078.
4. Yang ES Xia F (2010) BRCA1 16 years later: DNA damage-induced BRCA1 shuttling. FEBS J 277, 3079 3085.
5. Shen SX, Weaver Z, Xu X, Li C, Weinstein M, Chen L, Guan XY, Ried T Deng CX (1998) A targeted disruption of the murine Brca1 gene causes gamma-irradiation hypersensitivity and genetic instability. Oncogene 17, 3115 3124, doi :.
6. Deng CX (2006) BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Res 34, 1416 1426, doi:34/5/1416 [pii].
7. Boulton SJ (2006) Cellular functions of the BRCA tumour-suppressor proteins. Biochem Soc Trans 34, 633 645, doi: BST0340633 [pii].
8. Gudmundsdottir K Ashworth A (2006) The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 25, 5864 5874, doi: 1209874 [pii].
9. Mullan PB, Quinn JE Harkin DP (2006) The role of BRCA1 in transcriptional regulation and cell cycle control. Oncogene 25, 5854 5863, doi:1209872 [pii].
10. Zhang H, Somasundaram K, Peng Y, Tian H, Bi D, Weber BL El-Deiry WS (1998) BRCA1 physically associates with p53 and stimulates its transcriptional activity. Oncogene 16, 1713 1721, doi :. (Pubitemid 28175052)
11. Xu X, Qiao W, Linke SP, Cao L, Li WM, Furth PA, Harris CC Deng CX (2001) Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis. Nat Genet 28, 266 271, doi : 90108 [pii].
12. Jhanwar-Uniyal M (2003) BRCA1 in cancer, cell cycle and genomic stability. Front Biosci 8, s1107 s1117.
13. Prat J, Ribe A Gallardo A (2005) Hereditary ovarian cancer. Hum Pathol 36, 861 870, doi:S0046-8177(05)00283-2 [pii].
14. Whittemore AS, Gong G Itnyre J (1997) Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer. Am J Hum Genet 60, 496 504.
15. Szabo CI, Worley T Monteiro AN (2004) Understanding germ-line mutations in BRCA1. Cancer Biol Ther 3, 515 520, doi:841 [pii].
16. Easton DF, Deffenbaugh AM, Pruss D, Frye C, Wenstrup RJ, Allen-Brady K, Tavtigian SV, Monteiro AN, Iversen ES, Couch FJ et al. (2007) A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet 81, 873 883, doi:S0002-9297(07)63865-8 [pii].
17. Yudt MR, Jewell CM, Bienstock RJ Cidlowski JA (2003) Molecular origins for the dominant negative function of human glucocorticoid receptor beta. Mol Cell Biol 23, 4319 4330.
18. Song H, Hollstein M Xu Y (2007) p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat Cell Biol 9, 573 580, doi:ncb1571 [pii].
19. Tischkowitz M, Hamel N, Carvalho MA, Birrane G, Soni A, van Beers EH, Joosse SA, Wong N, Novak D, Quenneville LA et al. (2008) Pathogenicity of the BRCA1 missense variant M1775K is determined by the disruption of the BRCT phosphopeptide-binding pocket: a multi-modal approach. Eur J Hum Genet 16, 820 832, doi:ejhg200813 [pii].
20. Williams RS, Chasman DI, Hau DD, Hui B, Lau AY Glover JN (2003) Detection of protein folding defects caused by BRCA1-BRCT truncation and missense mutations. J Biol Chem 278, 53007 53016, doi : M310182200 [pii].
21. Scully R, Ganesan S, Vlasakova K, Chen J, Socolovsky M Livingston DM (1999) Genetic analysis of BRCA1 function in a defined tumor cell line. Mol Cell 4, 1093 1099, doi:S1097-2765(00)80238-5 [pii].
22. Holt JT, Thompson ME, Szabo C, Robinson-Benion C, Arteaga CL, King MC Jensen RA (1996) Growth retardation and tumour inhibition by BRCA1. Nat Genet 12, 298 302, doi :.
23. Randrianarison V, Marot D, Foray N, Cabannes J, Meret V, Connault E, Vitrat N, Opolon P, Perricaudet M Feunteun J (2001) BRCA1 carries tumor suppressor activity distinct from that of p53 and p21. Cancer Gene Ther 8, 759 770, doi :.
24. Cousineau I Belmaaza A (2007) BRCA1 haploinsufficiency, but not heterozygosity for a BRCA1-truncating mutation, deregulates homologous recombination. Cell Cycle 6, 962 971, doi:4105 [pii].
25. Monteiro AN, August A Hanafusa H (1996) Evidence for a transcriptional activation function of BRCA1 C-terminal region. Proc Natl Acad Sci USA 93, 13595 13599.
26. Somasundaram K, Zhang H, Zeng YX, Houvras Y, Peng Y, Wu GS, Licht JD, Weber BL El-Deiry WS (1997) Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1. Nature 389, 187 190, doi :.
27. Perrin-Vidoz L, Sinilnikova OM, Stoppa-Lyonnet D, Lenoir GM Mazoyer S (2002) The nonsense-mediated mRNA decay pathway triggers degradation of most BRCA1 mRNAs bearing premature termination codons. Hum Mol Genet 11, 2805 2814.
28. Ramus SJ Gayther SA (2009) The contribution of BRCA1 and BRCA2 to ovarian cancer. Mol Oncol 3, 138 150, doi:S1574-7891(09)00027-1 [pii].
29. Buisson M, Anczukow O, Zetoune AB, Ware MD Mazoyer S (2006) The 185delAG mutation (c.68-69delAG) in the BRCA1 gene triggers translation reinitiation at a downstream AUG codon. Hum Mutat 27, 1024 1029, doi :.
30. Anczukow O, Ware MD, Buisson M, Zetoune AB, Stoppa-Lyonnet D, Sinilnikova OM Mazoyer S (2008) Does the nonsense-mediated mRNA decay mechanism prevent the synthesis of truncated BRCA1, CHK2, and p53 proteins? Hum Mutat 29, 65 73, doi :.
31. Rodriguez JA, Au WW Henderson BR (2004) Cytoplasmic mislocalization of BRCA1 caused by cancer-associated mutations in the BRCT domain. Exp Cell Res 293, 14 21, doi:S0014482703005445 [pii].
32. Staff S, Nupponen NN, Borg A, Isola JJ Tanner MM (2000) Multiple copies of mutant BRCA1 and BRCA2 alleles in breast tumors from germ-line mutation carriers. Genes Chromosomes Cancer 28, 432 442, doi :: 4<432::AID-GCC9>3. 0.CO;2-J [pii].
33. Indraccolo S, Tisato V, Agata S, Moserle L, Ferrari S, Callegaro M, Persano L, Palma MD, Scaini MC, Esposito G et al. (2006) Establishment and characterization of xenografts and cancer cell cultures derived from BRCA1 -/- epithelial ovarian cancers. Eur J Cancer 42, 1475 1483, doi: S0959-8049(06)00321-2 [pii].
34. Evers B Jonkers J (2006) Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects. Oncogene 25, 5885 5897, doi:1209871 [pii].
35. Ludwig T, Fisher P, Ganesan S Efstratiadis A (2001) Tumorigenesis in mice carrying a truncating Brca1 mutation. Genes Dev 15, 1188 1193, doi :.
36. Brown MA, Nicolai H, Howe K, Katagiri T, Lalani elN, Simpson KJ, Manning NW, Deans A, Chen P, Khanna KK et al. (2002) Expression of a truncated Brca1 protein delays lactational mammary development in transgenic mice. Transgenic Res 11, 467 478.
37. Bachelier R, Vincent A, Mathevet P, Magdinier F, Lenoir GM Frappart L (2002) Retroviral transduction of splice variant Brca1-Delta11 or mutant Brca1-W1777Stop causes mouse epithelial mammary atypical duct hyperplasia. Virchows Arch 440, 261 266, doi :.
38. Fan S, Wang JA, Yuan RQ, Ma YX, Meng Q, Erdos MR, Brody LC, Goldberg ID Rosen EM (1998) BRCA1 as a potential human prostate tumor suppressor: modulation of proliferation, damage responses and expression of cell regulatory proteins. Oncogene 16, 3069 3082, doi :.
39. Fan S, Yuan R, Ma YX, Meng Q, Goldberg ID Rosen EM (2001) Mutant BRCA1 genes antagonize phenotype of wild-type BRCA1. Oncogene 20, 8215 8235, doi :.
40. Larson JS, Tonkinson JL Lai MT (1997) A BRCA1 mutant alters G2-M cell cycle control in human mammary epithelial cells. Cancer Res 57, 3351 3355.
41. Sylvain V, Lafarge S Bignon YJ (2002) Dominant-negative activity of a Brca1 truncation mutant: effects on proliferation, tumorigenicity in vivo, and chemosensitivity in a mouse ovarian cancer cell line. Int J Oncol 20, 845 853.
42. Xu X, Weaver Z, Linke SP, Li C, Gotay J, Wang XW, Harris CC, Ried T Deng CX (1999) Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol Cell 3, 389 395, doi:S1097-2765(00)80466-9 [pii].
43. Satagopan JM, Boyd J, Kauff ND, Robson M, Scheuer L, Narod S Offit K (2002) Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res 8, 3776 3781. (Pubitemid 35424769)
44. Johnson NC Kruk PA (2002) BRCA1 zinc RING finger domain disruption alters caspase response in ovarian surface epithelial cells. Cancer Cell Int 2, 7.
45. Johnson NC, Dan HC, Cheng JQ Kruk PA (2004) BRCA1 185delAG mutation inhibits Akt-dependent, IAP-mediated caspase 3 inactivation in human ovarian surface epithelial cells. Exp Cell Res 298, 9 16, doi : S0014482704001922 [pii].
46. O'Donnell JD, Johnson NC, Turbeville TD, Alfonso MY Kruk PA (2008) BRCA1 185delAG truncation protein, BRAt, amplifies caspase-mediated apoptosis in ovarian cells. In Vitro Cell Dev Biol Anim 44, 357 367, doi :.
47. O'Donnell JD, Linger RJ Kruk PA (2009) BRCA1 185delAG mutant protein, BRAt, up-regulates maspin in ovarian epithelial cells. Gynecol Oncol, doi:S0090-8258(09)00840-3 [pii].
48. Sood AK, Fletcher MS, Gruman LM, Coffin JE, Jabbari S, Khalkhali-Ellis Z, Arbour N, Seftor EA Hendrix MJ (2002) The paradoxical expression of maspin in ovarian carcinoma. Clin Cancer Res 8, 2924 2932.
49. Surowiak P, Materna V, Drag-Zalesinska M, Wojnar A, Kaplenko I, Spaczynski M, Dietel M, Zabel M Lage H (2006) Maspin expression is characteristic for cisplatin-sensitive ovarian cancer cells and for ovarian cancer cases of longer survival rates. Int J Gynecol Pathol 25, 131 139, doi : f 00004347-200604000-00003 [pii].
50. Thangaraju M, Kaufmann SH Couch FJ (2000) BRCA1 facilitates stress-induced apoptosis in breast and ovarian cancer cell lines. J Biol Chem 275, 33487 33496, doi : M005824200 [pii].
51. Hoshino A, Yee CJ, Campbell M, Woltjer RL, Townsend RL, van der Meer R, Shyr Y, Holt JT, Moses HL Jensen RA (2007) Effects of BRCA1 transgene expression on murine mammary gland development and mutagen-induced mammary neoplasia. Int J Biol Sci 3, 281 291.
52. Quaresima B, Romeo F, Faniello MC, Di Sanzo M, Liu CG, Lavecchia A, Taccioli C, Gaudio E, Baudi F, Trapasso F et al. (2008) BRCA1 5083del19 mutant allele selectively up-regulates periostin expression in vitro and in vivo. Clin Cancer Res 14, 6797 6803, doi:14/21/6797 [pii].
53. Sylvain V, Lafarge S Bignon YJ (2001) Molecular pathways involved in response to ionizing radiation of ID-8 mouse ovarian cancer cells expressing exogenous full-length Brca1 or truncated Brca1 mutant. Int J Oncol 19, 599 607.
54. Crugliano T, Quaresima B, Gaspari M, Faniello MC, Romeo F, Baudi F, Cuda G, Costanzo F Venuta S (2007) Specific changes in the proteomic pattern produced by the BRCA1-Ser1841Asn missense mutation. Int J Biochem Cell Biol 39, 220 226, doi:S1357-2725(06)00237-8 [pii].
55. Boutros R, Fanayan S, Shehata M Byrne JA (2004) The tumor protein D52 family: many pieces, many puzzles. Biochem Biophys Res Commun 325, 1115 1121, doi: S0006-291X(04)02409-X [pii].
56. Hartmann LC, Keeney GL, Lingle WL, Christianson TJ, Varghese B, Hillman D, Oberg AL Low PS (2007) Folate receptor overexpression is associated with poor outcome in breast cancer. Int J Cancer 121, 938 942, doi :.
57. Byrne JA, Balleine RL, Schoenberg Fejzo M, Mercieca J, Chiew YE, Livnat Y, St Heaps L, Peters GB, Byth K, Karlan BY et al. (2005) Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer. Int J Cancer 117, 1049 1054. doi :.
58. Miotti S, Canevari S, Menard S, Mezzanzanica D, Porro G, Pupa SM, Regazzoni M, Tagliabue E Colnaghi MI (1987) Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int J Cancer 39, 297 303.
59. Tirkkonen M, Johannsson O, Agnarsson BA, Olsson H, Ingvarsson S, Karhu R, Tanner M, Isola J, Barkardottir RB, Borg A et al. (1997) Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res 57, 1222 1227.
60. Kruk PA, Godwin AK, Hamilton TC Auersperg N (1999) Telomeric instability and reduced proliferative potential in ovarian surface epithelial cells from women with a family history of ovarian cancer. Gynecol Oncol 73, 229 236, doi:S0090-8258(99)95348-9 [pii].
61. Wong AS Auersperg N (2003) Ovarian surface epithelium: family history and early events in ovarian cancer. Reprod Biol Endocrinol 1, 70, doi : 1477-7827-1-70 [pii].
62. Salazar H, Godwin AK, Daly MB, Laub PB, Hogan WM, Rosenblum N, Boente MP, Lynch HT Hamilton TC (1996) Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J Natl Cancer Inst 88, 1810 1820.
63. Werness BA, Afify AM, Bielat KL, Eltabbakh GH, Piver MS Paterson JM (1999) Altered surface and cyst epithelium of ovaries removed prophylactically from women with a family history of ovarian cancer. Hum Pathol 30, 151 157.
64. Casey MJ, Bewtra C, Hoehne LL, Tatpati AD, Lynch HT Watson P (2000) Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds. Gynecol Oncol 78, 278 287, doi: S0090-8258(00)95861-X [pii].
65. You F, Chiba N, Ishioka C Parvin JD (2004) Expression of an amino-terminal BRCA1 deletion mutant causes a dominant growth inhibition in MCF10A cells. Oncogene 23, 5792 5798, doi : 1207739 [pii].
66. Annab LA, Terry L, Cable PL, Brady J, Stampfer MR, Barrett JC Afshari CA (2000) Establishment and characterization of a breast cell strain containing a BRCA1 185delAG mutation. Gynecol Oncol 77, 121 128, doi : S0090-8258(00)95734-2 [pii].
67. Thompson D Easton D (2002) Variation in BRCA1 cancer risks by mutation position. Cancer Epidemiol Biomarkers Prev 11, 329 336. (Pubitemid 34408211)
68. Gayther SA, Warren W, Mazoyer S, Russell PA, Harrington PA, Chiano M, Seal S, Hamoudi R, van Rensburg EJ, Dunning AM et al. (1995) Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet 11, 428 433, doi :.